
Wedbush raises Scholar Rock price target to $64 ahead of FDA decision on SMA drug.
Wedbush increased its price target for Scholar Rock to $64 from $58 and kept an "Outperform" rating ahead of the FDA's September 30 decision on Scholar Rock's investigational SMA drug, apitegromab. This drug could be the first muscle-targeted therapy...


